Background Approximately 5% of patients with celiac disease (CeD) do not respond to a gluten-free diet and progress to refractory celiac disease (RCD), a severe progression that is characterized by infiltration of intraepithelial T lymphocytes. Patients with RCD type II (RCDII) show clonal expansions of intraepithelial T lymphocytes that result in a poor prognosis and a high mortality rate through development of aggressive enteropathy-associated T-cell lymphoma. It is not known whether genetic variations play a role in severe progression of CeD to RCDII.
Patients and methods
We performed the first genome-wide association study to identify the causal genes for RCDII and the molecular pathways perturbed in RCDII. The genome-wide association study was performed in 38 Dutch patients with RCDII, and the 15 independent top-associated single nucleotide polymorphism (SNP) variants (P < 5 × 10 − 5 ) were replicated in 56 independent French and Dutch patients with RCDII. Results After replication, SNP rs2041570 on chromosome 7 was significantly associated with progression to RCDII (P = 2.37 × 10 − 8 , odds ratio = 2.36) but not with CeD susceptibility. SNP rs2041570 risk allele A was associated with lower levels of FAM188B expression in blood and small intestinal biopsies. Stratification of RCDII biopsies based on rs2041570 genotype showed differential expression of innate immune and antibacterial genes that are expressed in Paneth cells. Conclusion We have identified a novel SNP associated with the severe progression of CeD to RCDII. Our data suggest that genetic susceptibility to CeD might be distinct from the progression to RCDII and suggest a role for Paneth cells in RCDII progression. Eur J Gastroenterol Hepatol 30:828-837 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Background
Celiac disease (CeD) is characterized by intestinal damage owing to inflammation that is induced by exposure to dietary gluten in genetically susceptible individuals. A lifelong gluten-free diet is the only treatment available. However, a subset of patients with CeD does not respond to a gluten-free diet and become refractory [refractory celiac disease (RCD)]. Patients with RCD have persistent and more severe symptoms, serious malabsorption, crypt hyperplasia, and intestinal villous damage even after strict adherence to the gluten-free diet for at least 1 year [1] . The true prevalence of RCD is unknown, but it may affect 1% of patients with CeD [2, 3] . RCD is classified into two subtypes, RCD type-1 (RCDI) and RCD type-2 (RCDII), based on the phenotype of the intestinal intraepithelial lymphocytes (IELs) [1] .
IELs form a large population of lymphocytes located between the epithelial cells in the gut. In the normal adult human intestine as in RCDI, most IEL are polyclonal T cells with a CD8 + CD3 + TCRab + effector/memory phenotype. RCDII is characterized by the clonal expansion of IELs that express intracellular CD3 (iCD3 + ) but lack both surface CD3 (sCD3 − ) and CD8 (iCD3 + sCD3 − CD8 − IELs) [4, 5] . RCDII has a poor prognosis (5-year survival rate of <50%) [6] , and also because of the development of enteropathy-associated T-cell lymphoma (EATL). Diagnosis of RCDII is complex and involves a combination of several techniques such as multiplex PCR analysis to determine the clonality of T-cell receptor gene rearrangements and immunohistochemistry or flow cytometry to define the cell surface markers of IELs [3, [5] [6] [7] .
Although genome-wide association studies (GWAS) have identified 57 genetic loci associated with susceptibility to CeD [8] , nothing is known about the genetics of the progression toward RCDII. Because RCDII is a rare disease with a complicated diagnosis, only a small number of studies containing a limited number of RCDII cases (6-43 cases) have been described in the literature to date. The only known genetic risk factors that have been associated with RCDII are the same human leukocyte antigen (HLA) alleles that are associated with CeD susceptibility, although patients with RCDII are more often homozygous for HLA-DQ2 alleles (44-60%) than patients with CeD [9, 10] . To gain more insight into the genetic basis of progression to RCDII, we conducted the first GWAS in 38 Dutch patients with RCDII, with replication in two independent Dutch and French groups of 56 patients with RCDII. As the sample size was extremely small for performing a GWAS, we integrated the association results with genomic data, to identify significant association of 7p14.3 locus with RCDII progression.
Patients and methods

Patient recruitment and diagnosis
Written informed consent was obtained from all patients, with approval from the ethics committee or institutional review board of all participating institutions. All participants were of European ancestry. DNA samples were isolated from whole blood.
All individuals affected with RCDII were diagnosed according to strict diagnostic criteria, with their RCDII status confirmed by flow cytometry and/or the presence of CD3 + CD8 − intraepithelial lymphocytes in tissue biopsies and the detection of clonal TCRγ rearrangements in biopsies [5, 11] . Dutch individuals affected with RCDII from the discovery study (NL1, n = 38) and replication study (NL2, n = 15) were recruited from the outpatient clinic of the Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, the Netherlands. All patients had secondary RCDII, where they progressed to RCDII after some time responding to gluten-free diet. French RCDII cases (FR, n = 41) for the replication study were recruited from the Department of Gastroenterology, Hôpital Européen Georges Pompidou, Paris, France.
Dutch controls for the discovery study (NL1) were unselected healthy individuals as described previously [12] . Dutch controls for additional study (NL2) were all unrelated individuals selected from the Genome of the Netherlands (GoNL) project [13] . French controls (FR) were individuals who had participated in the Supplementation in Vitamins and Mineral Antioxidants study [14, 15] . Dutch patients with CeD were selected from the GWAS by Dubois et al. [12] .
Genotyping and genome-wide association study Dutch RCDII cases, Dutch healthy controls (NL1), and Dutch CeD cases were genotyped at University Medical Center Groningen (Groningen, the Netherlands) using the Illumina Hap550 BeadChip array (Illumina, San Diego, California, USA) according to the manufacturer's instructions (Supplementary Table S1 , Supplemental digital content 1, http://links.lww.com/EJGH/A294). The genotype calling steps and quality control of raw data were performed as described previously [12] . Additionally, markers were filtered and excluded from the data set for low minor allele frequency of less than 0.05, high number of missing genotypes (geno > 0.01), and for deviation from Hardy-Weinberg equilibrium (P < 0.000001) in controls. We excluded 28 478 single nucleotide polymorphisms (SNPs) based on the MAF threshold and 988 SNPs based on missing genotypes. No SNPs were removed using the Hardy-Weinberg equilibrium threshold. Our resulting data set contained 499 626 SNPs. We performed multidimensional scaling (MDS) analysis to check for population stratification using PLINK software [16] . We then tested the genomic inflation factor by logistic regression analysis to adjust for population stratification by including four MDS components as co-variables ( Supplementary  Fig. S1A -C, Supplemental digital content 2, http://links. lww.com/EJGH/A295).
Replication study
SNPs for the replication study in additional Dutch samples (NL2) and in French patients (FR) were selected based on their suggestive association (P < 5 × 10 − 5 ) in the discovery GWAS. Dutch and French RCDII cases were genotyped directly using TaqMan SNP Genotyping Assays on an ABI 7900HT system (Applied Biosystems, Foster City, California, USA). Genotyping of data and clustering were performed in the SDS 2.3 software (Applied Biosystems).
Genotypes of the Dutch controls (NL2) for replication study came from the GoNL, which used the Illumina HiSeq. 2000 for whole-genome sequencing analysis. The genotype data for replication were extracted from the GoNL website (http://www.nlgenome.nl/search/) release four. French controls for replication study (FR) were genotyped directly in the laboratory at the Centre Nationale de Genotypage (Evry, France) using the Illumina Human 610Quad Beadchip array according to the manufacturer's instructions with genotype call rate of more than 95% as previously described [15] . One RCDII SNP (rs1402582) did not pass the quality control parameters and was imputed as described previously [15] .
Association analysis
Standard case-control association analyses were performed independently for each study [discovery GWAS (NL1), CeD GWAS (CeD), Dutch replication study (NL2), and French replication study (FR)]. As the sample size was extremely small for a GWAS, we applied the two-tailed Fisher's exact test to be conservative to identify robust associations. We also compared the association P values at the top 15 loci selected for replication after correcting for population stratification by logistic regression by including the first four components as co-variables. The Cochran-Mantel-Haenszel test was used in the combined analysis of the two replication studies (NL2 + FR) and for all three studies in the metaanalysis (NL1 + NL2 + FR). Logistic regression analysis was used in the discovery study to test for the independence of association signals within the same region. Analyses were performed using PLINK v1.07 [16] . Regional association plots were generated with SNAP software [17] using the data set from the 1000-Genomes Project and the CEU population for r 2 calculation and recombination rate visualization. Manhattan plots were generated in Haploview 4.2 [18] .
Human leukocyte antigen analysis
Our samples were genotyped for the HLA-DQA1 and HLA-DQB1 genes using the 'six tagging SNPs' approach described by Monsuur et al. [19] . The Dutch GWAS cohorts (RCDII, controls, and CeD) were typed with the Illumina Hap550 BeadChip platform imputed with IMPUTE2 [20] . The RCDII samples from the replication study (NL2, FR) were directly genotyped for the six tagging SNPs using TaqMan SNP Genotyping Assays on an ABI 7900HT system (Applied Biosystems) and processed with the same protocol as the RCDII-SNPs. HLA types for French controls were obtained using six tagging SNPs from the imputed Illumina Human 660W-Quad BeadChip array as described previously [15] , and the HLA SNPs for the Dutch GoNL controls in the replication study (NL2) were extracted from the whole-genome sequencing data.
Two studies have shown a strong association of RCDII with homozygosity for the HLA-DQ2 allele [9, 10] . Therefore, we categorized our samples based on the HLA-DQ2 status into individuals homozygous for HLA-DQ2 (DQ2/DQ2), heterozygous for HLA-DQ2 (DQ2/DQX), and individuals without the HLA-DQ2 risk allele (DQX/ DQX), and compared the allele frequencies in RCDII individuals, patients with CeD, and healthy controls.
Regression analyses to test the interaction between HLA and non-HLA SNPs
Logistic regression analysis was performed to test whether SNP rs20471570 is independently conferring risk to RCDII or is interacting with HLA. The outcome variable is disease status. In the first step, the SNP of interest (rs20471570) and the potential confounders (HLA-DQ2 haplotype and sex) were analyzed in an univariable logistic regression analysis. In the following step, the SNP of interest and potential confounders were combined in a multivariable logistic regression analysis. We tested for potential interaction between the SNP of interest and HLA-DQ2 haplotype or sex by adding interaction terms.
Building the RCDII risk prediction model
To evaluate the added value of the SNPs of interest for the prediction of RCDII in patients with CeD, the predictive performance of the complete model, including the rs20471570, the HLA-DQ2 haplotype, and sex, was compared with the predictive performance of the model with the HLA-DQ2 haplotype and sex alone [21] . Goodness of fit was analyzed using Nagelkerke's pseudo-R 2 , and the discriminative ability was evaluated by constructing the receiver operator characteristic curve and calculating the c-statistic area under the curve (AUC). We used the regression modeling strategies and PredictABEL (assessment of risk prediction models) packages in R-studio for these analyses [22] .
Expression quantitative trait loci analysis in blood
We performed expression quantitative trait loci (eQTL) analysis of replicated RCDII-SNPs. The eQTL analysis was executed in RNA-sequencing data obtained from peripheral blood mononuclear cells of 629 unrelated Dutch individuals from the population-based LifeLines Deep cohort [23] as described in the study by Ricaño-Ponce et al. [24] . The expression data were normalized and corrected based on the principal component analysis, and cis-eQTL mapping was performed as described previously [24, 25] . Associations were tested by nonparametric Spearman's rank correlation test. In the meta-eQTL analysis, we applied a Bonferroni correction to define a significance threshold of P less than 0.005 based on the number of SNP-transcript pair tested.
Genotype-expression correlation in biopsies
Intestinal biopsies from 10 patients with RCDII from discovery cohort were investigated according to the United European Gastroenterology criteria. The methods of biopsy sampling, RNA isolation [26] , and details of microarray hybridization have been described previously [27] . The raw data have been deposited in the EBI ArrayExpress with the accession-ID 'E-MTAB-4613'. The expression data were quantile-normalized using the Illumina BeadStudio program. The quantile-normalized and log 2-transformed expression values were stratified according to the genotypes at rs2041570 and tested for significant differences using the Wilcoxon rank test.
Genotype-dependent differential expression
Expression levels of genes in RCDII biopsies were compared between four nonrisk (GG) and three risk homozygous (AA) samples at rs2041570. The significant difference in expression levels was tested by two-tailed t-test. As the number of samples was not sufficient to achieve statistical power to obtain differentially expressed genes after correction for multiple testing, we only relied on genes that show more than a five-fold difference between genotype with an un-corrected P value less than 0.05 (Supplementary Table  S2 , Supplemental digital content 3, http://links.lww.com/ EJGH/A296). Pathway enrichment analysis on differentially expressed genes was done using ConsensusPathDB [28] .
Results
Known CeD SNPs are not associated with RCDII susceptibility
To identify novel genetic loci associated with RCDII progression, we performed a genome-wide association study using Dutch patients with RCDII (Fig. 1a) . We tested 499 626 SNPs from the Illumina Hap550 BeadChip array for association in 38 individuals with RCDII and 846 matched population-based controls (Supplementary Table  S1 , Supplemental digital content 1, http://links.lww.com/ EJGH/A294). The MDS analysis on both cases and controls indicated no population stratification ( Supplementary  Fig. S1A , Supplemental digital content 2, http://links.lww. com/EJGH/A295). Correcting for the four MDS components using logistic regression analysis indicated the λ GC is 1.03 ( Supplementary Fig. S1C , Supplemental digital content 2, http://links.lww.com/EJGH/A295), without any major differences at the top-associated loci. As the sample size for the RCD2 GWAS was small, we relied on P values from Fisher's exact test for further analysis. We observed 180 SNPs from the HLA region on chromosome 6 to be significantly associated (P < 5 × 10 − 8 ) with RCDII (Fig. 1b) , which were in strong LD with HLA-DQ2 allele. When testing SNPs from any of the 39 known CeD non-HLA genetic loci [8] , none were found to be significantly associated with susceptibility to RCDII after correction for multiple testing (Bonferroni P < 0.001) (Supplementary Table S3 , Supplemental digital content 4, http://links.lww. com/EJGH/A297), suggesting that the SNPs associated with CeD susceptibility may not contribute to RCDII progression.
SNP rs2041570 is associated with RCDII progression
Next, to find non-HLA variations specifically associated with RCDII progression, we performed association analysis using 734 Dutch CeD as controls and 38 patients with RCDII on the 15 most strongly associated SNPs (P < 5 × 10 Table S5 , Supplemental digital content 6, http://links.lww. com/EJGH/A299), whereas two additional SNPs, rs7324708 on 13q22.1 and rs205047 on 17p12, showed improved association (P < 5 × 10
). All these three SNPs confer very strong risk for progression to RCDII ( Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/EJGH/ A295), with ORs of around 2 (OR range = 1.92-2.33) in the meta-analysis.
HLA and SNP rs2041570 loci independently confer risk to RCDII progression
As HLA is a known risk factor for RCDII, we tested its interaction with rs2041570. We confirmed that most patients with RCDII were homozygous HLA-DQ2 (>64.4%) , respectively. HLA, human leukocyte antigen.
GWAS on refractory celiac disease Hrdlickova et al. www.eurojgh.comcompared with 42.3% in Dutch CeD (Fig. 2a) . We observed a similar frequency of the homozygous risk genotype AA at rs2041570 in patients with CeD (17% in NL) and controls (16.3% in NL, 18% in FR), but the frequency was twice as high in patients with RCDII (>38%) (Fig. 2b) . We observed high frequency of risk allele A at rs2041570 among patients with RCDII who were also homozygous for HLA-DQ2 (53.3%) compared with CeD (28.6%) and healthy controls (3.8%) (Fig. 2c) .
We performed logistic regression analysis to test whether the rs2041570 and HLA alleles independently confer risk to RCDII using Dutch patients with RCDII (n = 38) and Dutch patients with CeD (n = 734) for whom genotype data at both HLA and non-HLA SNPs were available. We observed that both HLA-DQ2 and the risk allele A at rs2041570 are independently associated with RCDII (P DQ2 = 0.0018, OR DQ2 = 2.63; P rs2041570 = 0.0004, OR rs2041570 = 2.25) ( Table 1 ). Combining the potential cofounders (HLA-DQ2, rs2041570, and sex) in one genetic risk model using multivariable logistic regression analysis improved the association with RCDII (Table 1) . To test for potential interactions between rs2041570 and HLA-DQ2 or sex, we included interaction terms in our models. None of the interaction terms were significantly associated with RCDII, suggesting that there is no significant interaction between rs2041570 and HLA-DQ2 and between rs2041570 and sex (data not shown). To evaluate the added value of rs20471570 for the prediction of RCDII in patients with CeD, a risk model was built that included rs20471570, the HLA-DQ2 haplotype, and sex. Combining HLA-DQ2 with sex and the risk allele A for rs2041570 showed the best discrimination with an AUC of 0.735 compared with an AUC of 0.627 for the 'HLA-DQ2 only' model (Fig. 2d) .
Genotype-expression correlation suggests FAM188B as a candidate gene
To identify the causal RCDII gene from the chromosome 7 locus, we first tested whether rs2041570 was strongly correlated with another SNP that alters the protein structure of any gene in the locus using HaploReg SNP annotation tool [29] . None of the SNPs in linkage disequilibrium (r 2 >0.4) with rs2041570 were coding variants (Supplementary Table S6 , Supplemental digital content 7, http://links.lww.com/EJGH/ A300) but are all located in noncoding region of the genome, suggesting a possible regulatory function of this locus (Fig. 3a) . We therefore performed cis-eQTL mapping using RNAsequencing data and genotype data from 629 healthy-donor blood samples (LifeLines cohort) [24] and observed that the risk allele A at rs2041570 was associated (P = 0.01; Fig. 3b ) with lower expression levels of FAM188B (family with sequence similarity 188, member B), a gene 315 kb distal of rs2041570 (Fig. 3a ), but not with other genes encoded in the same region (Supplementary Table S7 , Supplemental digital content 8, http://links.lww.com/EJGH/A301). When we combined the LifeLines cohort eQTL data with RNA-sequencing data from the 1000-Genomes project, we found strong replication (Meta-eQTL P = 0.008) of the effect of rs2041570 on FAM188B levels (Supplementary Table S7 , Supplemental digital content 8, http://links.lww.com/EJGH/A301). We also confirmed these results in biopsies from patients with RCDII where the risk allele A also showed lower levels of expression of FAM188B (AA + AG vs. GG, P = 0.057; Fig. 3c ), whereas expression levels of other genes in this locus were not associated with rs2041570 genotypes (Supplementary Fig. S3A , Supplemental digital content 2, http://links.lww.com/EJGH/ A295 and Supplementary Fig. S3B , Supplemental digital content 2, http://links.lww.com/EJGH/A295).
Genotype-dependent expression analysis at rs2041570 implicates RCDII gene in intestinal innate immune function
Genotype-expression correlation analyses suggested FAM188B as a putative causal gene at rs2041570. However, it is not sufficient to exclude the role of other genes in the locus. Therefore, we attempted to explore the downstream pathways affected by this locus in trans. As the intestinal biopsies of the carriers of rs2041570*AA and rs2041570*GG genotypes are indistinguishable in cellular composition, the comparison of gene expression difference between genotypes helps us to exclusively extract the molecular pathways associated with the RCDII locus at 7p14.3. To enhance our understanding of the molecular pathways disrupted in RCDII that are caused by rs2041570, we stratified RCDII biopsies into rs2041570*AA and rs2041570*GG genotypes to identify differentially expressed genes (Supplementary Table S2 , Supplemental digital content 3, http://links.lww.com/EJGH/A296). We found 26 genes showing an average of more than five-fold difference (P < 0.05) in expression, with 18 genes up-regulated and eight genes down-regulated in the samples carrying the rs2041570*AA risk genotype (Fig. 4a) . Pathway enrichment analysis on these differentially expressed genes indicated a significant overrepresentation (P = 6.63 × 10 Table S8 , Supplemental digital content 9, http://links.lww.com/EJGH/ A302).
Interestingly, we found a dramatic nearly 60-fold upregulation of the C20orf114 gene (Fig. 4b) in the biopsies carrying the rs2041570*AA risk genotype. In addition, we observed differential expression of many epithelial innate defense genes (TCN1, SERPINA5, MMP7, SCGB3A1, PGC, and SH2D1B). C20orf114, also known as BPIFB1, encodes for the long palate, lung, and nasal epithelium clone protein-1 (LPLUNC1). LPLUNC1 has been shown to be expressed in Paneth cells [30] and to function as an innate immune modulator to Vibrio cholera infection [29] [30] [31] . Furthermore, we found altered expression of multiple Paneth-cell-specific genes (DEFA1, DEFA5, DEFA6, and DEFB1) in an rs2041570-genotype-dependent manner (Fig. 4c) . We then tested the expression specificity of FAM188B by querying the Human Protein Atlas portal (http://www.proteinatlas.org), we observed that FAM188B is expressed at low levels in tissues but ubiquitously. However, much stronger FAM188B expression was seen in the glandular cells of the intestine (Supplementary Fig. S4 , Supplemental digital content 2, http://links.lww.com/EJGH/A295), suggesting that some of the glandular cells, for example, goblet or Paneth cells, may have higher FAM188B expression. Together, these observations suggested that FAM188B could function in the context of Paneth cells in RCDII.
Discussion
In the present study, we report the results of the first GWAS on RCDII, an extreme clinical phenotype of CeD. We confirm the strong association of RCDII with the HLA locus and identify SNP rs2041570 on chromosome 7 as an independent and strong risk factor (OR = 2.34) for RCDII progression. By integrating genomics data, we suggest chromosome 7p14.3 locus harbors a potential causal gene that may work to dysregulate intestinal innate immune pathways in RCDII.
The SNPs that contribute to disease prognosis can be different from the variants that contribute to disease susceptibility. This has also been shown for Crohn's disease, in which SNPs at FOXO3A, XACT, IGFBP1-IGFBP3 and the MHC region were found to be significantly associated with disease prognosis but not associated with Crohn's disease susceptibility [32] [33] [34] . In this study, we found no significant evidence for association of known CeD non-HLA loci with either susceptibility to or progression to RCDII, suggesting that different variants may contribute to prognosis of the disease. However, it is difficult to make this conclusion definite owing to very small sample size of RCDII as compared with big GWAS for CeD. Nevertheless, a genetic risk model using both HLA and the SNP rs2041570 significantly improved the risk estimation for progression to RCDII in patients with CeD (Fig. 2d ), although the model needs to be tested in an independent RCDII cohort. In addition, these two currently known genetic loci are still insufficient to predict all the patients at increased risk of progression to RCDII, who therefore need to be closely monitored. Two other loci, rs7324708 and rs20547, also showed suggestive associations with RCDII (Fig. S2 , Supplemental digital content 2, http://links.lww.com/EJGH/A295). These SNPs are located within the introns of KLF12 and SHISA6 genes, respectively. Future studies are needed to understand whether these genes are causally associated with RCDII or not. There are likely to be additional genes that contribute to RCDII, but given the small numbers of patients with RCDII, GWAS alone is insufficient to detect them. The referent categories are female, DQ2 allele, and risk allele A at rs2041570. HLA, human leukocyte antigen; L95, lower bound of 95% confidence interval for odds ratio; OR, odds ratio; Pr( > |Z|), probability calculated by Wald Z-test; SNP, single nucleotide polymporphism; U95, upper bound of 95% confidence interval for odds ratio.
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The identification of additional genes will also reveal the molecular pathways by which the disease progresses and carries the potential to reveal novel targets for the treatment of RCDII. We have previously shown that genotype-dependent response profiling can identify specific pathways altered by the risk allele, in which a critical role for CLEC12A in an ATG16L1 genotype-dependent manner was identified in Crohn's disease [35] . When we applied a similar approach here, using RCDII biopsies, our data show that individuals carrying two copies of the rs2041570 risk allele have differential expression of many intestinal innate defense genes and antimicrobial defensins that may also play a role in Paneth cell function. Paneth cells are known to secrete granules containing bactericidal proteins like defensins and lysozyme, which in turn regulate the microbiome of the gut [36] . This is an interesting observation as Paneth cell abnormalities have been suggested to play a role in RCD [36, 37] and in Crohn's disease [38] [39] [40] . Given this important role of Paneth cells in Crohn's disease and a suggestive role in RCDII, it may be that these two conditions share a similar pathogenesis related to a disturbed interaction with intestinal microbiota. In addition, some of the gut innate immune genes that were expressed in a rs2041570-risk-genotype-dependent manner in RCDII biopsies were shown to be important for gut bacterial infections such as Vibrio cholera [29, 30] . It is therefore worth examining whether the interaction between the gut microbiome and the gut mucosal immunity contributes to the RCD. A preliminary analysis of the gut microbiome composition in healthy individuals [41] stratified by the SNP rs2041570 showed a reduction in the abundance of Roseburia inulinivorans, a butyrate-producing bacterium (P = 0.005) in carriers of the risk allele A (Supplementary Fig. S5 , Supplemental digital content 2, http://links.lww.com/EJGH/ A295). Butyrate-producing bacteria are assumed to play a role in gut health [42] and their numbers are shown to be decreased in patients with inflammatory bowel disease [43] . The association between the RCDII SNP and Roseburia inulinivorans in healthy individuals, although preliminary, supports a model in which patients with CeD can be predisposed to an altered gut microbiome owing to their genetics and thereby have an increased risk of developing RCDII. However, and not mutually exclusive, a primary defect in the epithelial cells and more specifically in their ability to control inflammation may play an important role in the development of RCDII. rs2041570 locus may contribute to maintain chronic inflammation in patients following strict gluten-free diet and, by this way, acquisition of oncogenetic events involved in lymphomagenesis. Besides HLA-DQ2 genotype, evidence of rs2041570 locus enlarges the spectrum of non-gluten-dependent mechanisms involved in RCDII pathogenesis. Combination of such various factors is concordant with the rarity of this malignant complication and the possibility of co-existing in the same family of both uncomplicated celiac and RCDII cases, as it was the case for at least two patients of the series. However, additional functional studies are required to understand how rs2041570 locus regulates innate immune pathways in Paneth cells in relation to gut microbial composition.
There are also some limitations to the study. First, the sample size of our GWAS is extremely small owing to the rarity of the disease. This may have limited the robust comparison between CeD and RCDII at variants associated with these diseases. Second, we cannot exclude the possibility that genes other than FAM188B are also involved in RCDII pathogenesis owing to the relatively low number of intestinal biopsy samples used for eQTL analysis.
Conclusion
We show for the first time that SNP rs2041570 is an independent risk factor for RCDII progression, and that disease progression and susceptibility are distinct from each other. GWAS on refractory celiac disease Hrdlickova et al.
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